MedTrace Logo

To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions

NCT00947128 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2017-03-28

No results posted yet for this study

Summary

To demonstrate the relative bioavailability study of Ondansetron HCl 24 mg tablets under non-fasting conditions.

Conditions

Interventions

DRUG

Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)

DRUG

Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)

Sponsors & Collaborators

Principal Investigators

  • Soran Hong, M.D. · Novum Pharmaceutical Research Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
58 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2004-10-31
Completion
2004-10-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00947128 on ClinicalTrials.gov